Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Mtb CoaBC

Financiado

Cerrado

CoaBC from the Coenzyme A pathway of Mycobacterium tuberculosis as an antimicrob...

CoaBC from the Coenzyme A pathway of Mycobacterium tuberculosis as an antimicrobial drug target The increasing prevalence of drug-resistant microorganisms worldwide and the shortage of novel antimicrobial chemotherapeutics in the pipeline places our capacity to treat infectious diseases under serious threat. Antimicrobial ch... ver más

24/08/2021

THE CHANCELLOR MAS...

183K€

Presupuesto del proyecto: 183K€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-08-24

MSCA-IF-2017: Individual Fellowships

I+D

Cerrada hace 7 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

THE CHANCELLOR MASTERS AND S...

183.45K€ | Lider

ACCIONA ENERGIA

294.44K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

deCrYPtion Decrypting Mycobacterium cytochrome P450 CYP physiological... 213K€ Cerrado

NovAnI Indentification and optimisation of novel anti infective age... 1M€ Cerrado

NABATIVI Novel Approaches to Bacterial Target Identification Validat... 7M€ Cerrado

NATT New Approaches to Target Tuberculosis 4M€ Cerrado

AnLeadOp Antibiotic Lead Optimization 150K€ Cerrado

ANTIPATHOGN Identification and validation of novel drug targets in Gram... 8M€ Cerrado

Duración del proyecto: 40 meses Fecha Inicio: 2018-04-12
Fecha Fin: 2021-08-24

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 183K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The increasing prevalence of drug-resistant microorganisms worldwide and the shortage of novel antimicrobial chemotherapeutics in the pipeline places our capacity to treat infectious diseases under serious threat. Antimicrobial chemotherapies with novel modes of action are desperately needed. However, the development of such therapies is a formidable task associated with a high failure rate. This has been partly attributed to the limited diversity of high-throughput screening libraries and difficulties converting potent inhibitors of targets into cell-active leads. We intend to use a novel, unified and efficient approach to target, in multiple pathogenic microorganisms, the conserved biosynthesis pathway of Coenzyme A (CoA), an essential enzyme cofactor. Using powerful fragment-based approaches, pioneered in Cambridge, we have developed a series of highly potent inhibitors of the most vulnerable enzyme target in the bacterial CoA biosynthesis pathway of Mycobacterium tuberculosis (Mtb), Mtb CoaBC, a target which has recently been validated in experiments using conditional knockdown mutants in CoA pathway genes. We will focus our initial efforts in confirming that tuberculosis (TB) can be combatted with small molecule CoaBC inhibitors. In addition, we propose to assess the cross-species activity of these inhibitors on a panel of other pathogenic microorganisms, leveraging this research and potentially generating leads for antibiotics against these other pathogens.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores